Roivant’s Mosliciguat Shines in Phase 2, Sending ROIV Shares Toward All‑Time High Roivant’s Mosliciguat Shows Promise in Pulmonary Hypertension Trial GSK's Bold Gambit: $1.4 Billion Bet on Aiolos Bio for Pulmonary Hypertension Breakthrough GSK's Bold Move: A $1.8 Billion Bet on the Future of Pulmonary Hypertension Treatment